Physician profile
David E Lewandowski
NPI 1316333198
$5,457.70
in general payments reported to CMS, 2019-2025
14 companies · $4,317 in 2025
The $4,317 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2021: $100 · 2022: $222 · 2023: $191 · 2024: $410 · 2025: $4,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,685 · Travel and Lodging: $1,169 · Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,685.00 |
| Travel and Lodging | $1,168.57 |
| Food and Beverage | $1,063.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,823.10 | 2019-2025 | Wainua, Farxiga |
| Abbott Laboratories | $1,427.77 | 2025 | Triclip |
| Pfizer INC. | $372.37 | 2019-2025 | |
| Medtronic, INC. | $252.04 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $165.91 | 2023-2025 | Amvuttra, Onpattro |
| Amgen INC. | $78.15 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $73.60 | 2023-2025 | Watchman Access System |
| Edwards Lifesciences Corporation | $59.60 | 2019-2024 | |
| Lantheus Medical Imaging, INC. | $52.29 | 2024 | |
| Novartis Pharmaceuticals Corporation | $47.98 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.87 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $39.86 | 2023-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $18.16 | 2025 | Camzyos |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lewandowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.